Relmada Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Relmada Therapeutics

17/03/2023 11:11

* Relmada Therapeutics Inc  RLMD.OQ   RLMD.O  is expected
to show
no change in quarterly revenue when it reports  results on March
21 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Relmada
Therapeutics Inc
is for a loss of $1.33 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $8.25​, above​ its last closing price
of $2.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -1.44       -1.45      -1.31     Beat    9.6
 Jun. 30 2022  -1.29       -1.27      -1.33     Missed  -4.5
 Mar. 31 2022  -1.24       -1.27      -1.40     Missed  -10.6​
 Dec. 31 2021  -1.66       -1.83      -1.80     Beat    1.6
 ​​Sep.        -1.61       -1.60      -2.44     Missed  -52.8
 30 2021                                                
 Jun. 30 2021  -1.49       -1.47      -1.56     Missed  -5.9​
 Mar. 31 2021  -1.42       -1.39      -1.34     Beat    3.9
 Dec. 31 2020  -1.08       -1.16      -1.31     Missed  -13.1
 This summary was machine generated March 17 at 11:10 GMT.  All
figures in US dollars  unless otherwise stated